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Introduction
Cardiovascular disease (CVD) was responsible for over 840,000 deaths in the United
States in 2016 and costs an estimated $352 billion annually in both direct and indirect costs.
Approximately every 40 seconds, an American will have an acute myocardial infarction (AMI),
and at a similar rate an American will have a stroke. In patients who experienced AMI from
2010 to 2016, statin use at hospital discharge increased from 92% to 99%. Nonetheless,
cardiovascular disease remains the leading cause of death in the United States and more than
one million coronary events are expected to occur in individuals in 2019; approximately
335,000 of those cases will be recurrent coronary events. 1 Understanding the risk factors for
CVD and then reducing those risks have the potential to decrease the impact of this disease.
Of the multiple risk factors for CVD, dyslipidemia ranks high. The essence of this “lipid
hypothesis” generated decades ago was the assumption of a positive relationship between lowdensity lipoprotein cholesterol and the incidence of coronary disease. Although, significant
evidence supporting elevated cholesterol as a primary risk factor for cardiovascular disease and
major cardiovascular events was found, critics of the hypothesis believed that the postulation
of causality was incompletely supported by those findings. 2 Accordingly, lowering low-density
lipoprotein cholesterol with an HMG-CoA reductase inhibitor might provide incomplete
protection from cardiovascular disease as is possibly evidenced by the residual risk a patient
may have despite statin therapy.
The first HMG-CoA reductase inhibitor was discovered in 1978 and became
commercially available in 1987 when the US FDA advisory panel voted unanimously for
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approval of the medication after clinical trials demonstrated its ability to significantly reduce
plasma cholesterol compared with dietary modifications and other available medications such
as bile acid sequestrants, fibrates, and nicotinic acid. Subsequent studies and trials with HMGCoA reductase inhibitors (aka, statins) further demonstrated substantial risk reduction for
cardiovascular events such as myocardial infarction and stroke without any increase in noncardiovascular mortality.3 Statins have since revolutionized the treatment of hypercholesterolemia and are the agents of choice for treatment and prevention of atherosclerotic
cardiovascular disease. Indications for prescribing statins have broadened over time with the
implementation of the American College of Cardiology (ACC) risk stratification calculator that
gauges the risk of atherosclerotic cardiovascular disease (ASCVD) based on lipid levels and
other risk factors. The ACC partnered with the American Heart Association (AHA) and created
guidelines that stratified risk levels, and then specified the intensity of statin therapy according
to the degree of risk. However, despite using these guidelines and the significant reduction in
cardiovascular events attributed to the lipid lowering effects of statins, many patients still had
residual risk for CVD.
Hence, other means of reducing harmful lipids were researched. Nevertheless, statins
were proven extremely efficacious. For this reason, instead of simply substituting statins with
another agent, add-on therapy for lipid reduction was also explored along with investigating
effects produced solely by other agents. Omega-3-fatty acid supplements, eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), were examined for lipid-lowering effects. Indeed,
both EPA and DHA decreased both triglycerides (TG) and non-high-density lipoproteins (nonHDL) and thereby, could possibly reduce the CVD risks and events.
2

EVOLVE II was a randomized controlled trial (RCT) that investigated the efficacy and
safety of Epanova®, a lipid-regulating agent containing omega-3 carboxylic acid, which is a
mixture of both EPA and DHA. An intermediate dose of Epanova® compared with olive oil
significantly lowered TG and non-HDL levels in patients with severe hypertriglyceridemia
(SHTG). Based on these findings, a clinical benefit from this agent for prevention of CVD risk and
events was proposed.4
The ROMANTIC trial was another randomized controlled trial that examined the safety
and efficacy of adding omega-3 fatty acids (FAs) to statin therapy in patients with persistent
elevations in TG despite statin therapy. This multicenter, double-blind, parallel group, placebocontrolled study was just an eight-week trial that showed reductions in TG and non-HDL.5
Both EVOLVE II and ROMANTIC were limited by small sample sizes (162 and 201
participants, respectively), restricted generalizability (only Caucasians and middle-aged Asians,
respectively, were studied) and short durations (12 weeks and 8 weeks, respectively).
Nonetheless, these trials revealed significant improvements in TG and non-HDL levels, resulting
from EPA and DHA combination therapy. By virtue of the lipid hypothesis, the evidence from
these studies could be extrapolated to mean that omega-3 FAs may reduce CVD events, but
these studies were not designed to measure this outcome.
A murine study, however, did test the effect of omega-3 FAs on CVD, but without
examining lipid levels. In 2015 Madingou et al. used 115 male Sprague-Dawley mice, to
investigate the impact of EPA and DHA alone and in combination on induced myocardial infarct
size. The mice experienced diminished infarct size with both EPA and DHA individually, but did
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not obtain the same cardio-protection with the combination of EPA and DHA.6 Researchers
speculated that this disparity might be due competition for like receptors. Alternatively, instead
of receptor competition, the achievement of cardio-protection could have been mediated by
increased protein kinase B (Akt) activity (with EPA and DHA alone) and decreased caspace-3
activity (with DHA only). Although the results from this study cannot be applied directly to
humans, the findings did suggest a mechanism whereby omega-3-FAs could be cardioprotective.
Other researchers have explored the specific relationships between EPA or DHA and
cardiovascular disease. A study in Japan by Nishizaki et al. examined patients’ levels of EPA,
DHA, and arachidonic acid (AA) in relation to a diagnosis of acute coronary syndrome (ACS).
Patients with the lowest EPA/AA ratio had a greater probability of experiencing ACS compared
with patients with the lowest DHA/AA ratio.7 A similar analysis by Iwamatsu et al. found that
the found that the EPA/AA ratio, which was low, was more closely associated with ACS than the
DHA/AA ratio.8
Trials such as ROMANTIC or EVOLVE II have suggested that supplementation with
polyunsaturated fatty acids (PUFAs), specifically omega-3-fatty acids, may confer cardiovascular
benefits via reducing harmful lipids. However direct evidence establishing that EPA therapy
lowers CVD events is lacking. Nonetheless, studies linking low EPA levels with an increased risk
of ACS suggest a role for EPA supplementation in patients with residual CVD despite optimized
statin therapy. Thus, whether adding EPA to statin therapy reduces CVD events in addition to
reducing the CVD risk factors of dyslipidemia will be examined.
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Discussion
In a retrospective cohort-based analysis including more than 11,000 patients, after
adjustments for patient characteristics and concurrent medical therapy including statin use,
Greene et al. found that omega-3 fatty acid treatment was independently associated with
decreased risk of cardiovascular events in individuals after experiencing acute myocardial
infarction.9 In a subsequent prospective, open-label, blind end point randomized trial, Nosaka
et al. determined that early initiation of EPA combined with a statin in patients treated with
successful primary PCI (percutaneous coronary intervention) after ACS reduced subsequent
cardiovascular events.10 This study was the first to specifically assess the additive effect of EPA
with a statin on cardiovascular events including death, nonfatal myocardial infarction, nonfatal
stroke, and occurrence of new lesions requiring PCI or CABG. The trial also investigated the
incidence of hospitalization for heart failure in those who received EPA and statin combination
therapy compared to statin monotherapy. Absolute risk reduction was calculated at 11.0% and
EPA/AA ratios were notably increased within a few days of initiating EPA at a dose of 1800
mg/day. Though outcomes were assessed at 3-month intervals for only one year, the possible
anti-inflammatory and anti-arrhythmic effects of EPA in the early phase after acute coronary
syndrome may have contributed to both short- and long-term benefits and outcomes for
patients.
The posited anti-inflammatory effects of EPA from the above trial were consistent with
results from a previous open-label study using surrogate endpoints in a small sample of at-risk
patients. In that study, Nishio et al. assessed the impact of EPA and statin therapy compared to
statin monotherapy on the stabilization of vulnerable plaques in patients with untreated
5

dyslipidemia and vulnerable plaques identified by thin cap fibroatheroma detected by
multivessel optical coherence tomography (OCT). No significant difference in levels of lowdensity lipoprotein or cardiovascular events were found between the two groups of 15 patients
each. Nonetheless, after nine months, the EPA group had a greater increase in fibrous-cap
thickness and a greater decrease in lipid length and arc, findings indicative of increased plaque
stability. Researchers also noted decreased pentraxin-3 levels as well as decreased macrophage
accumulation in the EPA and statin group both findings indicative of reduced inflammation.11
These results suggested a benefit secondary to suppression of arterial inflammation, and
researchers believed this mechanism would contribute to greater stabilization of unstable
plaques and ultimately lead to decreased cardiovascular events. When linked to subsequent
research, this mechanism provides a potential means to reduce cardiovascular risk that statins
alone do not achieve.
Niki et al. further explored the effect of EPA on coronary plaque components and local
inflammatory cytokines after adding purified EPA ester to the existing treatment regimens of
patients with dyslipidemia. Their blocked-randomization, open-label, single-center study
provided evidence that the addition of EPA to strong statins was associated with a reduction in
the lipid content of plaques in coronary arteries as observed by integrated backscatter
intravascular ultrasound. Although some inherent limitations to IB-IVUS and the sample size of
59 patients are limitations, a significant reduction in lipid volume and a significant increase in
fibrous volume were only noted in the group receiving EPA in addition to a statin. Similarly,
inflammatory cytokines, pentraxin-3 and monocyte chemoattractant protein-1 were not
different in the group receiving statin monotherapy, but decreased in those receiving EPA.12
6

A more recent study by Watanabe et al. examined the effects of combination therapy
with EPA and pitavastatin (PTV) compared with PTV alone on coronary plaque regression and
stabilization as measured by integrated backscatter intravascular ultrasonography (CHERRY).
This prospective, randomized, non-blinded, parallel, multicenter study which studied 193
patients with coronary heart disease following PCI, and which had greater power than previous
related studies, produced evidence that EPA and statin combination therapy achieved
significant lipid volume reduction as well as significant reduction in total atheroma volume
compared to statin monotherapy.13 Moreover, researchers noted no significant difference in
the incidence of adverse events between the two groups including undesired elevation of lowdensity lipoprotein cholesterol. These results were congruent with previous reports detailing
the anti-inflammatory and anti-oxidative effects conferred by EPA therapy and suggested that
EPA was safe and efficacious for reducing residual cardiovascular risks that existed despite
optimized statin therapy.
Conclusion
Statins remain the pharmacologic agents of choice for reducing the risk of
atherosclerotic cardiovascular disease. Despite treatment with high intensity statins, many
patients have residual risk of CVD. Omega-3 fatty acids have been identified as a potential
means to address this residual risk and do so via mechanisms different from those of HMG-CoA
reductase agents. Although research specifically supporting the efficacy of EPA over other
polyunsaturated fatty acids is limited, retrospective and observational studies suggest a strong
correlation between low EPA levels (but not DHA levels) and increased cardiovascular disease
events. Furthermore, unlike DHA, EPA has not been associated with unintended increases of
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low-density lipoprotein cholesterol (a CVD risk factor). Evidence from several recent trials
revealed that EPA therapy, in addition to statins, reduced major cardiovascular events such as
death, myocardial infarction, or stroke, and decreased various biomarkers and risk factors for
cardiovascular events without increasing non-cardiovascular mortality. The proposed and
identified mechanisms by which EPA reduced cardiovascular risk support the prediction of both
short and long-term cardio-protective benefits and suggest potential benefits and indications
for other conditions such as dementia and depression (EPA’s use for these latter conditions are
also being investigated). Additionally, researchers have not defined any significant increase in
adverse effects when comparing EPA and statin combination therapy with statin monotherapy.
Accordingly, clinicians may consider prescription EPA for patients, especially for those who have
significant residual cardiovascular risk despite treatment with a high intensity statin.
Nonetheless, further research will be necessary to confirm EPA’s long-term safety, its efficacy
for clinical (rather than surrogate) outcomes, patient acceptance, and potential applications for
its use in both primary and secondary prevention of cardiovascular disease. Finally, improving
risk stratification tools may direct (or limit) certain treatments to specific subsets of the
population and thus optimize utilization of resources.
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